{"name":"PharPoint Research, Inc.","slug":"pharpoint-research-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Phenobarbital Sodium Injection","genericName":"Phenobarbital Sodium Injection","slug":"phenobarbital-sodium-injection","indication":"Seizure disorders and epilepsy","status":"marketed"}]}],"pipeline":[{"name":"Phenobarbital Sodium Injection","genericName":"Phenobarbital Sodium Injection","slug":"phenobarbital-sodium-injection","phase":"marketed","mechanism":"Phenobarbital sodium is a barbiturate that enhances inhibitory GABA neurotransmission in the central nervous system, producing sedative, hypnotic, and anticonvulsant effects.","indications":["Seizure disorders and epilepsy","Acute seizure management","Sedation and anxiety","Status epilepticus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQekk0ZXZpYWJzNXZhQXFLdXAzYnJFM3V2WGh1Z0VzY0NPUTgxN0ZWX2paY29pOW1ZMFNmYXhrSUI0SHpyVTJPOWZQT0pBUnZiWDNCYWtDSGFrUTFTNmhrOWFqTXU5QmNBTVk0WEVLMFptUjgyMG1pZ0I0WTlZdTAzOXBUVnVfUDAySzIxTDM4SzBiOVdhUldxbEN3dDk?oc=5","date":"2023-08-25","type":"pipeline","source":"The Business Journals","summary":"2023 Best Places to Work Awards: PharPoint Research - The Business Journals","headline":"2023 Best Places to Work Awards: PharPoint Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE91V3M5V3BJVTJlR0ZvRmROSnQtSmRrUGI0UEtBd3pOeTNkREVZTzdhYWd0V3FrVXZQZF9DcS1rSzloQk5sRmE1azV1Tno3cE5aa00zbUNGdW9jZjQ?oc=5","date":"2022-09-10","type":"trial","source":"EurekAlert!","summary":"DeFi trial: Smart design and impressive results for the benefit of patients with rare cancers - EurekAlert!","headline":"DeFi trial: Smart design and impressive results for the benefit of patients with rare cancers - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPc3BnclRLMzNBeGVaQWRfNDF4cGoyM2JqZmh4eURvOW12QlB1SWQ5NGstb1pVNEJNMFBRUTZoSEY0TDhmVWY3aEJlQWh3bnhWVGZ4QXg1cks2NlRnNkU1NllGNllqWlpMeHN2ckI1eVZNbzhKdFpEX3pBNmxkb0w4UFp1aExaRnh5d0VWYlh1N3RKNEhoOE85amt3ZmxkRnY0RXdGWElnTm4xSE9pWC1LbENFQlpyVzItZ3E5dHhGOHI3U1lYcldjdVBscl9veWs?oc=5","date":"2019-08-22","type":"pipeline","source":"WilmingtonBiz","summary":"Firm's Expansion Expected To Lead To New CRO Jobs In Wilmington - WilmingtonBiz","headline":"Firm's Expansion Expected To Lead To New CRO Jobs In Wilmington","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}